- In 2021, Delic’s investments and acquisitions allowed for an annualized revenue run-rate of over $9MM
- Going into the new year, the company looks forward to opening additional ketamine infusion treatment clinics, growing them by 15 within the next 18 months
- Delic’s growth has been attributed to the strong demand for alternatives to current treatments for mental health conditions
- Its management is confident that the foundations laid down so far position Delic for growth and profitability in 2022 and beyond
2021 was an excellent year for
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), as indicated in the company’s recent update (
https://ibn.fm/HokJs), marked by key acquisitions and furthering its goal of providing the highest standard of care to patients. According to the management team, these achievements position the company well for growth and profitability in 2022 and beyond.
In November 2021, Delic closed the acquisition of Ketamine Wellness Centers (“KWC”), an enterprise that operated 10 ketamine infusion treatment clinics across the United States (
https://ibn.fm/K3Vug). The purchase brings the total number of operational Delic clinics to 12, making it the largest chain of wellness centers providing ketamine treatments in the United States. Delic is also confident that within the next 18 months, there will be 15 more clinics in operation, ultimately sealing its position as the undisputed leader in the segment.
“At Delic, we have built the most profitable model for scaling the best-in-class care directly to patients through the largest network of mental health clinics in the U.S.,” noted Matt Stang, the Co-founder and Chief Executive Officer (“CEO”) of Delic.
All acquisitions for the 2021 financial year were geared towards accelerating Delic’s growth trajectory and establishing its self-sustaining ecosystem of businesses that currently comprises Ketamine Infusion Centers (“KIC”), Delic Labs, KWC and a number of media properties. In total, these investments allowed for the company to realize an annualized revenue run-rate of over $9MM, a figure which the company is confident will be surpassed in 2022.
Matt Stang, the Co-founder and Chief Executive Officer of Delic, has been keen to note that the company’s success has been primarily driven by the growing demand for alternatives to mainstream treatments for mental health conditions influenced by the ongoing pandemic.
“We are seeing a strong demand for alternatives to current treatments with lasting outcomes and less side effects,” Mr. Stang noted.
Delic’s media properties, including Meet Delic, arguably the world’s largest annual psychedelic wellness event, also demonstrate the power of the Delic ecosystem of businesses. In November 2021, it attracted over 2,500 attendees and over 2,000 inbound calls to clinics in a span of two days.
Through achievements such as these, coupled with the company’s aggressive expansion and rollout, Delic is differentiating itself, with management confident in growth and profitability in 2022 and beyond.
For more information, visit the company’s website at
www.DelicCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at
https://ibn.fm/DELCF
